Japan, July 14 -- CHARITE-UNIVERSITAETSMEDIZIN BERLIN,MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN has got intellectual property rights for 'USE OF APTAMER IN THERAPY AND/OR DIAGNOSIS OF AUTOIMMUNE DISEASE.' Other related details are as follows:
Application Number: JP,2023-006274
Category (FI): A61P11/00,A61P25/28,A61P9/00,A61P37/06,A61P37/02,A61P27/06,G01N33/53@N,C12N15/115@Z,A61K31/7088,A61P1/00,A61P9/12,A61P17/06,A61P17/00,A61P25/00,A61P13/08
Stage: PROBLEM TO BE SOLVED: To provide a use of an aptamer in therapy and/or diagnosis of an autoimmune disease.SOLUTION: According to the present invention, an aptamer consists of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2, and 3 for use in therapy and/or diagnosis of an autoimmune disease. Here, the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclampsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.SELECTED DRAWING: None (Grant)
Filing Date: Jan. 19, 2023
Publication Date: March 16, 2023
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
